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SUMMARY
Schistosomiasis remains one of the most prevalent parasitic diseases in developing countries. After malaria, schistosomiasis
is the most important tropical disease in terms of human morbidity with signiﬁcant economic and public health conse-
quences. Although schistosomiasis has recently attracted increased focus and funding for control, it has been estimated that
less than 20% of the funding needed to control the disease in Africa is currently available. In this article the following issues
are discussed: the rationale, development and objectives of the Schistosomiasis Control Initiative (SCI)-supported pro-
grammes; the management approaches followed to achieve implementation by each country; mapping, monitoring and
evaluation activities with quantiﬁable impact of control programmes; monitoring for any potential drug resistance; and
ﬁnally exit strategies within each country. The results have demonstrated that morbidity due to schistosomiasis has been
reduced by the control programmes. While challenges remain, the case for the control of schistosomiasis has been
strengthened by research by SCI teams and the principle that a national programme using ‘preventive chemotherapy’ can
be successfully implemented in sub-Saharan Africa, whenever the resources are available. SCI and partners are now
actively striving to raise further funds to expand the coverage of integrated control of neglected tropical diseases (NTDs) in
sub-Saharan Africa.
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INTRODUCTION
World leaders have determined to make strong and
sustained eﬀorts to reduce extreme poverty, as set
by the 2000 United Nations Millennium Declara-
tion and reaching the ambitious eight Millennium
Development Goals (MDGs; www.un.org/millen
niumgoals). Progress has been made towards these
MDGs and in particular MDG 6, which aims ‘to
Combat HIV/AIDS, Malaria, and Other Diseases’
(Fenwick and Webster, 2006; Paul, 2008). Schisto-
somiasis, or bilharzia as it is sometimes referred to,
is one such ‘Other Disease’.
Schistosomiasis is a chronic and debilitating dis-
ease, second only to malaria in terms of parasite-
induced human morbidity and mortality. It con-
tinues to threaten millions of people, particularly the
rural poor in the developing world. Of some 779
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million people exposed, an estimated 200 million are
infected, more than half of whom are symptomatic
and at least 20 million exhibit severe disease mani-
festations (Steinmann et al. 2006). Schistosomes, the
causative agents, are digenetic trematodes with the
adult worms inhabiting the blood vessels of humans,
and an asexual reproduction stage in speciﬁc aquatic
and amphibious snails. Human infection with
Schistosoma japonicum and S. mansoni is associated
with chronic hepatic and intestinal ﬁbrosis, whilst
S. haematobium infections can lead to ureteric and
bladder ﬁbrosis, and calciﬁcation of the urinary tract.
The latter two species of schistosomes which are
prevalent in sub-Saharan Africa are responsible for a
great burden on human health, and some 280 000
deaths annually due to late stage liver ﬁbrosis, hae-
matemesis and urinary system complications (van
der Werf et al. 2003).
The possible methods available to control schisto-
somiasis have long been recognized as improved
water supplies and sanitation, snail control and
preventive chemotherapy for infections in the
human (and sometimes animal) host (WHO, 1993).
Provision of clean water supplies and improved
sanitation to the poorest communities is still
lacking, and snail control has proved to be diﬃcult,
expensive and/or environmentally unacceptable.
‘Preventive chemotherapy’ has emerged as themajor
tool, because it is a safe and low-cost intervention
producing a rapid impact (Fenwick and Webster,
2006). In fact, in sub-Saharan Africa, where socio-
economic development is slow and provision of
clean water and sanitation facilities are less than
satisfactory, preventive chemotherapy with the tar-
get of reducing intensity of infection, and thus
morbidity, constitutes a much more realistic target
for schistosomiasis control. Currently, preventive
chemotherapy is the mainstay of the World Health
Organization (WHO)-recommended strategy against
schistosomiasis as described in their manual (WHO,
2006).
Since Egypt, China and Brazil have implemented
successful schistosomiasis control programmes, in-
ternational interest and political commitment for
control of helminthic diseases in sub-Saharan Africa
has grown substantially with schistosomiasis now
placed on the international health agenda (Utzinger
et al. 2003; Stothard and Gabrielli, 2007). Major
shifts in global health policy have resulted in a
number of control programmes using preventive
chemotherapy being implemented on a national scale
in sub-Saharan Africa (Fenwick, 2006). This has
been made possible by the wide availability of the
safe and eﬀective drug praziquantel (PZQ), mainly
due to its signiﬁcant reduction in price (>90% since
1990), so that in 2008 tablets are available at US$
0.07–0.08 from several manufacturers which means
the cost of the drug to treat a child is approximately
US$ 0.20 (Fenwick and Webster, 2006).
This article describes the rationale, development
and implementation of the Schistosomiasis Control
Initiative (SCI; http://www.sci-ntds.org/) and high-
lights some of the recent key SCI publications and
relevant literature. We hope that by sharing SCI
experiences, new support for schistosomiasis control
can be attracted as it is estimated that less than 20% of
those who need treatment are currently being oﬀered
the drug (Hotez et al. 2007b). This is despite control
being possible at a cost of below US$ 0.50 per person
per year, which includes drug cost (US$ 0.20), ad-
vocacy, information, education and communication
(IEC) and social mobilization, delivery, training and
monitoring and evaluation.
DEVELOPMENT OF THE SCI PROGRAMMES
The move towards national control programmes in
sub-Saharan Africa was facilitated by an award from
the Bill and Melinda Gates Foundation (BMGF;
http://www.gatesfoundation.org) Global Health
Program in 2002, to the SCI for the implementation
and evaluation of control of schistosomiasis (Brooker
et al. 2004; Fenwick, 2006; Garba et al. 2006;
Kabatereine et al. 2006a). Six countries were selec-
ted by October 2003 for full support: Burkina
Faso, Mali, Niger, Uganda, Tanzania and Zambia
(Fenwick, 2006). The countries each proposed a
diﬀerent implementation approach and management
structure for their large-scale schistosomiasis con-
trol. This was readily accepted because the BMGF
required SCI to test the ‘proof-of-principle’ of
national scale, Ministry of Health (MoH)-led schisto-
somiasis control programmes. SCI is based in
Imperial College London and operated with the
principle that all programmes were country owned
and run, with SCI staﬀ oﬀering technical and other
assistance, but not as expatriates living in-country.
Programmes were based in the MoH in the respec-
tive country, and SCI oﬀered support to improve
the national health system. All programmes com-
plied with WHO recommendations in World Health
Assembly resolution WHA 54.19 of 2001 (WHO,
2002).
One of the SCI’s ﬁrst actions was to adopt inte-
gration of intestinal worm control. Whereas the SCI
was initially established to target a single disease (i.e.
schistosomiasis using PZQ), it was very soon realized
that wherever there is schistosomiasis, co-infections
with soil-transmitted helminths (STHs) such as
Ascaris lumbricoides, Trichuris trichiura and hook-
worm are the norm rather than the exception (Geiger,
2008). The fact that STHs and schistosomiasis can
be treated safelywith the co-administration of a single
400 mg tablet of albendazole (ALB) or 500 mg tablet
of mebendazole costing just US$ 0.02 with prazi-
quantel made this integration an obvious step. Thus
the SCI decided from the outset to oﬀer treatment
for STH infections together with schistosomiasis, as
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recommended by WHA 54.19, and consequently
adapted its objectives (WHO, 2002) which are sum-
marized in the Box 1.
APPROACH TO IMPLEMENTATION AND
MANAGEMENT IN SCI-SUPPORTED COUNTRIES
The reported treatment numbers of people in each
SCI-supported country are displayed in Table 1.
Based on the SCI premises and objectives afore-
mentioned, the following section describes the
strategy and management approach used by each
supported country.
East Africa
Uganda. Uganda was the ﬁrst country which
launched a SCI-supported control programme in
April 2003. Uganda started with a pilot phase
covering >400 000 schoolchildren (7- to 15-year-
old) and selected communities (Kabatereine et al.
2006b). The country of Uganda is divided into dis-
tricts and then several sub-counties within each
district, and the surveys were conducted in all
the districts known to be endemic for schisto-
somiasis. This resulted in pilot interventions being
implemented in one sub-county in each of the 18
most aﬀected districts (out of 56), after which the
programme expanded to cover increasing numbers of
schoolchildren and communities in 23 districts in the
subsequent years (as shown in Table 1). In schools,
the programme oﬀered mass treatment with PZQ
and ALB to all children delivered by schoolteachers
who had previously been trained speciﬁcally on
control of schistosomiasis and STH infections and
how to treat using the two drugs. Within com-
munities, internally selected community drug dis-
tributors (CDDs) provided treatment to all eligible
individuals within targeted communities. Excluded
from treatment were young children below 94 cm in
height, following standard WHO guidelines, and
those who were unwell. The annual mass treatment
campaign has subsequently been carried out in
April/May each year alongside the MoH’s ‘Child
Days Plus strategy’ (Kabatereine et al. 2006a).
Local health staﬀ were encouraged to deliver some
general health education messages simultaneously
with treatment in an attempt to raise awareness about
the helminth infections, the control programme
and the beneﬁts of treatment. IEC materials that
have been translated into various local languages and
distributed to schools and communities were pre-
pared and used, and where possible messages were
delivered over local FM radio stations.
The ‘National Bilharzia and Worm Control
Programme’ was managed by the Vector Control
Table 1. Number of persons treated (million) for schistosomiasis and STH control in SCI-supported
countries from 2003 to 2008
Year Uganda
Burkina
Faso Niger Mali Tanzania Zambia
Total
by year
2003 0.433 0 0 0 0.100 0 0.533
2004 1.230 1.027 0.672 0 0.442 0 3.371
2005 2.988 2.296 2.010 2.598 2.952 0 12.844
2006 1.511 2.819 1.560 2.175 0.384 0.556 9.005
2007 1.812 0.750 2.066 0.647 2.650 0.245 8.170
2008 1.497* 2.697 5.284* 0* 1.243 0 10.721
Total by
country
9.471 9.589 11.592 5.420 7.771 0.801 44.644
* Treatment incorporated into the new integrated NTD control programme.
Box 1 Objectives of SCI
$ To encourage development of sustainable
schistosomiasis and STH control programmes in
sub-Saharan Africa.
$ In the selected countries: to reach at least 75% of
school-aged children (which in most countries
would be from 6 to 15-year-old) and other high-
risk groups with chemotherapy, namely PZQ
and ALB; and thereby reducing prevalence and
intensity of schistosomiasis and STH infections;
as well as reducing schistosomiasis-related mor-
bidity in high risk groups; and burdens due to
STH infections in the targeted populations.
$ To create a demand for sustained schistosomiasis
and STH control.
$ Topromote access to anthelminthic drugs and good
case management in the regular health system.
$ To develop a rigorous monitoring and evaluation
plan which will generate the information required
to determine whether or not the objectives have
been met (Brooker et al. 2004).
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Division of the MoH, and details about the mana-
gerial aspect of the programme can be found in the
2006 publication by Kabatereine et al. (2006a).
Tanzania. Based on the available resources, which
were insuﬃcient to reach all schools in the country
and certainly not all the adults at risk, theMoH (now
Ministry of Health and Social Welfare, MoHSW) on
mainland Tanzania made the strategic decision
to adopt a school-based de-worming approach, tar-
geting at ﬁrst approximately ﬁve million children
(aged 7–13 years) in highly endemic areas (this
represents 50% of the children in the country).
The ‘National Schistosomiasis and Soil-transmitted
Helminth Control Programme’ (NSSCP) was es-
tablished based in the MoH and was co-ordinated
by the existing ‘National School Health Programme’
in collaboration with the Ministry of Education
(MoE) (Kabatereine et al. 2006a).
As a ﬁrst step in identifying target areas for con-
trol, a questionnaire survey was distributed to every
primary school in the country to solicit data on
blood-in-urine and other related symptoms for uri-
nary schistosomiasis (Clements et al. 2008a, b). On
the basis of the results of the questionnaire survey
and a large parasitological mapping survey conduc-
ted in northwestern Tanzania (for both S. mansoni
and S. haematobium) (Clements et al. 2006), six re-
gions in the Lake andWestern zones and ﬁve regions
along the Indian Ocean coast (comprising a total of
65 districts – or approximately half of the country)
were selected as highly endemic priority regions to
receive the ﬁrst round of mass drug administration
(MDA) within the school system (Kabatereine et al.
2006a). The strategy for treatment was reﬁned for
the next round of MDA using the WHO guidelines
on frequency of treatment according to prevalence
levels of disease, but also taking into account
the logistics of implementing such a massive pro-
gramme, and ﬁtting into school opening and closing
times.
SCI identiﬁed additional private funding to
treat heavily aﬀected communities surrounding Lake
Victoria and on some islands (particularly ﬁshermen
in Mwanza region) where intestinal schistosomiasis
is a signiﬁcant public health issue (Malenganisho
et al. 2008). This resulted in treatment being oﬀered
to the whole population on Ukerewe district in both
2006 and 2008, although coverage was not as high as
would have been hoped for.
In addition to the support oﬀered to Tanzania
mainland, the SCI supported theMoHSW to imple-
ment control programmes on the two major islands
which constitute Zanzibar. The research and control
work on Zanzibar was carried out in collaboration
with the Natural History Museum (London, UK),
and with co-funding from the Health Foundation
(Southgate et al. 2005). On Unguja Island, the
‘Kick-Out Kichocho Programme’ was managed by
the Helminth Control Laboratory and treated all
school-aged children across the island for STH with
ALB and those children residing in urinary schisto-
somiasis (kichocho in Kiswahili) endemic areas with
PZQ. Drugs were distributed each year through
primary schools. On Pemba Island, by contrast, the
Kichocho Control Programme was managed by the
Public Health Laboratory-Ivo de Carneri. Due to
the high prevalence levels of schistosomiasis in the
Pemba population, treatment was delivered to all
eligible individuals in every household by CDDs on
the island on an annual basis. After two rounds of
MDA, the prevalence levels within the community
had dropped to a level whereby further treatment
was only warranted within the school-aged popu-
lation, thus the programme continued to conduct
MDA each year but limited to within primary
schools (unpublished SCI data).
Zambia. The ‘Zambian Bilharzia Control Pro-
gramme’ (ZBCP) was established in 2004 to develop
a MoH and MoE joint strategy for bilharzia and
worm control. The MoE was already in receipt of a
grant from the United States Agency for Inter-
national Development (USAID) for implementing
training and treatment in some schools on a small
scale in two provinces, Eastern and Southern, which
was known as the ‘School Health and Nutrition
programme’ (SHN). The SCI contribution was used
to expand the coverage in both of these provinces to
ensure that all schools including community (i.e.
non-government) schools (schoolchildren aged 7–13
years) and communities in high-risk areas were
oﬀered treatment. Based on mapping surveys the
ZBCP implemented the programme in Southern and
Eastern provinces through trained teachers and
community health workers. During 2005 (phase 1),
the programme was piloted by expanding coverage
in the districts where the SHN had carried out
several annual treatments in some but not all schools.
In phase 2 the following year, there was a scale-up
in order to treat more individuals in schools and
high-risk communities requiring treatment in the
remaining districts (Kabatereine et al. 2006a).
West Africa
One of the reasons why Mali, Niger and Burkina
Faso were selected for support was because these
three countries are all inland and contiguous. The
separate MoH staﬀ agreed to co-operate and collab-
orate and regularly share experiences with each other
in a spirit of regional collaboration.
Capacity-building workshops and training and
IECcampaigns took place in all three aforementioned
countries annually during 2004–2007. Programme
staﬀ from the three countries participated in
an ultrasound training session for schistosomiasis-
related morbidity (in Niger) and training in project
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ﬁnancial management (in Burkina Faso and Zambia).
Several means of communication were tested for
advocacy purposes and IEC activities: these included
productions of television sketches, publicity leaﬂets,
posters, comic strips for children and radio spots. All
were aimed at increasing public knowledge on the
diseases in an attempt to educate the population
about behaviours and activities that would lead
to schistosomiasis and could often be avoided. Staﬀ
from all three programme countries worked closely
together and assisted each other when needed.
They joined in process monitoring evaluations which
took place collaboratively in each country to enable
the programme managers to monitor the coverage
achieved by their treatment programmes and the
acceptance of the drugs by the targeted populations
(Garba et al. 2006).
Burkina Faso. In West Africa, when SCI was
launched, S. haematobium was the predominant
schistosome species, and prevalence levels in chil-
dren were very high, over 80% in some school-aged
children groups. The national control programme in
Burkina Faso opted not to extend the programme
beyond school-aged children during the ﬁrst two
rounds of coverage but to concentrate the resources
on reaching the heavily infected children in endemic
areas. Details about the national schistosomiasis
control programme supported by the SCI have
been described elsewhere (Gabrielli et al. 2006;
Koukounari et al. 2007). In brief, the control strategy
adopted by the MoH was modiﬁed from the WHO
guidelines and involved treatment once every two
years to all school-aged children (aged 5–15 years).
The ﬁrst treatment with PZQ and ALB was im-
plemented during 2004 and 2005 in a staggered two-
phased campaign. Due to the low school enrolment
rate in Burkina Faso (<50%), treatment was carried
out both through schools and communities to
reach as many as possible of the school-aged children
not attending school. As described previously
(Gabrielli et al. 2006), the treatment campaign was
co-ordinated and supervised by the MoH staﬀ,
but involved education authorities and local com-
munities. A speciﬁc national ‘treatment week’ was
designated inOctober each year and health personnel
at each level (regional, district and dispensary) were
mobilized. Drug delivery in schools was carried out
by trained school teachers. To reach non-enrolled
children, health workers and CDDs manned ﬁxed
units at dispensary and mobile units that visited
villages or hamlets actively seeking school-aged
children not attending school. The decision to stag-
ger treatment to deliver only every two years was
based on previous experience with S. haematobium
in western Africa (Garba et al. 2004) and on the
fact that the ongoing monitoring and evaluation
activities showed a satisfactory reduction in pre-
valence and intensity of infection 12 months
post-treatment (Koukounari et al. 2007; Toure´ et al.
2008).
Mali. Mali was one of the ﬁrst countries in sub-
Saharan Africa to initiate a national schistosomiasis
control programme in the 1980s implemented by the
Malian MoH in partnership with the World Health
Organization and funds from the German Technical
Co-operation (DeutscheGesellschaft fu¨r Technische
Zusammenarbeit, GTZ) at the time (Brinkmann
et al. 1988). In the following years many planned
activities were not implemented due to limited ﬁ-
nancial resources but ﬁnally in 2004 national control
activities recommenced in the country with support
from the SCI which expanded later as a scale-up to
reach greater numbers of people (Garba et al. 2006).
Collaborating units participating in the implemen-
tation of the National Control Programme were the
National Institute of Research in Public Health
(Institut National de Recherche en Sante´ Publique
(INRSP)) and the Disease Prevention and Control
Division (Direction Nationale de la Sante´) of the
Malian MoH. The latter decided upon school-based
and community-based distribution through trained
teachers, health workers and/or trained CDDs as
appropriate.
Niger. In Niger, the decision by the MoH was also
to aim for expanded coverage beyond school-aged
children to include high-risk communities, women of
child-bearing age, pregnant and lactating women
in communities where prevalence was over 50%
(Savioli et al. 2004). This decision was based on pre-
treatment prevalence surveys which showed that
schistosomiasis was found with a high prevalence
distribution in all these groups particularly along
the Niger River and the irrigated areas but also
near temporary ponds. Niger’s National Schisto-
somiasis and Soil-Transmitted Control Programme
(PNLBG) was launched at 2004 (Garba et al.
2006). The decision to include pregnant women
was taken after the WHO cleared praziquantel for
treatment of pregnant women (Olds, 2003). After
two rounds of annual treatment, because of the
drug cost and logistics of reaching into the country
rural areas, and because of the eﬀectiveness of the
PZQ treatments, Niger also decided to adopt the
strategy of oﬀering treatment to people every two
years. The distribution of PZQ and ALB to the
selected target populations each year was via trained
school teachers and CDDs reaching out to the target
populations.
ACHIEVEMENTS
Each country laid out milestones for mapping,
strategy development and treatment. By the end of
2008, a total of 40 million doses of PZQ have been
administered to school-aged children and adults at
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high risk of schistosome-related morbidity for
schistosomiasis and many more treated for STH
infections because of SCI support to deworming
programmes in non-schistosomiasis areas (the num-
ber of treatments in each country is summarized in
Table 1). It is noteworthy that Burkina Faso was the
ﬁrst country in the WHO African Region to achieve
nationwide coverage with anthelminthic drugs
against three major so-called neglected tropical dis-
eases (NTDs), namely lymphatic ﬁlariasis, schisto-
somiasis and STH. However, the SCI-supported
schistosomiasis and STH control programmes in
these countries are not just about drug delivery, but
also about impact upon public health and human
morbidity as well as capacity-building through ex-
tensive training workshops (ﬁnancial, ultrasound,
microscopy, health education, etc.) and hands-on
training during implementation of the programmes
in the countries.
Mapping activities
SCI has invested in large-scale, cross-sectional
parasitological surveys to provide data for mapping
schistosome and STH infections in all SCI-
supported countries. In West Africa, coordinated
mapping surveys in Burkina Faso, Mali and Niger
followed a united plan to collect data for a regional
map showing prevalence, intensity of infection and
risk of schistosomiasis and intestinal helminths
(Clements et al. 2008c). Data were collected during
2004–2006 in order to establish the distribution of
schistosomiasis and STH infections, and the result-
ing maps assisted in the development of optimal
treatment strategies in each country. In addition,
the 2004–2006 mapping data from Mali were com-
pared with 1984–1989 data from national pre-
intervention cross-sectional schistosomiasis surveys
using Bayesian geostatistical models with the aim
to investigate changes in the spatial distribution of
schistosomiasis in the country following a decade of
donor-funded control and a further 12 years without
control (Clements et al. 2009). The main ﬁnding of
this study was that the spatial distribution was re-
markably similar between the two examined time
periods. In East Africa, separate mapping surveys
were conducted in large areas of Tanzania (including
four regions in the north-west), in Zambia (including
all of Southern province), and in Uganda where SCI
survey data from a limited number of locations was
combined with existing, recent national survey data
collected by the national schistosomiasis control
programme in Uganda.
All the surveys were school-based and were con-
ducted using standardised protocols, with the aim to
collect samples from 30 boys and 30 girls in each
selected school. The numbers of schools and children
to be surveyed in each country was calculated by a
statistician to give robust results for a wide area using
a relatively small, yet cost-eﬀective survey (Clements
et al. 2006). The mapping data were plotted using a
geographical information system (GIS) and were
linked to spatial information on climate, elevation
and proximity to large perennial water-bodies.
Statistically robust Bayesian geostatistical models
were then used to predict prevalence and intensity
of infection across the SCI-supported control pro-
gramme areas. This has enabled more eﬃcient allo-
cation of national control programme resources by
focusing attention on high prevalence and intensity
clusters within each country (Clements et al. 2006).
To our knowledge, the SCI-supported programmes
are the ﬁrst to invest in such extensive datasets for
the purposes of mapping NTDs and the ﬁrst to
implement Bayesian geostatistical methods to facili-
tate the planning of real-world, large-scale disease
control.
Monitoring and evaluation activities
All disease control operations require careful moni-
toring and evaluation to demonstrate the results
achieved, both to the donors and to the host govern-
ments. Therefore SCI invested in process monitor-
ing, drug evaluation and morbidity measurements
throughout the programme in each supported
country. To start with, all drugs purchased for the
project were sampled and tested for quality using the
British Government Chemist’s Laboratory, and
fortunately all samples tested were of an acceptable
quality (Fenwick, 2008).
Morbidity studies required detailed validation
of the direct and indirect indicators of schistosome
and STH-related morbidity, along with appropriate
statistical analysis. To this end, cohorts of children
and adults were recruited for longitudinal follow-up
throughout the programmes in each country. In each
country, sample sizes were determined in order to
allow for predicted reductions in prevalence and in-
tensity of infection, but also allowing for a drop out
rate of up to 40% each year. In each school and
community selected, individuals were invited to
participate in the annual follow-up examinations
and provide stool (for STH and S. mansoni), urine
(for S. haematobium) and ﬁnger tip blood samples
for haemaglobin examination. Sub-samples of the
recruited cohorts were clinically examined using
ultrasound to determine liver or bladder ﬁbrosis. The
results have added signiﬁcantly to the knowledge
of impact and cost-eﬀectiveness of large scale com-
munity drug treatments (Koukounari et al. 2006a, b,
2007; Kabatereine et al. 2007; Tohon et al. 2008).
The timetable of completed follow-up visits for
monitoring purposes in each country is shown in
Table 2. Data have been double entered and analyzed
as soon after collection as possible. Results have
either already been published in the peer-reviewed
literature or are under preparation for publication.
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Evaluation of impact of the control programmes
on disease
Recent research eﬀorts aim to better deﬁne the im-
pact of schistosomiasis on children’s health and
in particular upon morbidity; also to quantify
the speciﬁc beneﬁts of mass treatment in schistoso-
miasis endemic settings. More particularly, one
recent study (Koukounari et al. 2006a) using data
from the ‘Ugandan Bilharzia and Worm Control
Programme’, evaluated the relationship between
S. mansoni and hookworm infection, anaemia and
mass treatment. Haemoglobin levels in 2788 children
among diﬀerent schistosomiasis and/or hookworm
infection intensity categories at baseline and one year
after treatment were also quantiﬁed through soph-
isticated statistical modeling. This study suggested
that children heavily infected with S. mansoni
or hookworm had signiﬁcantly lower haemoglobin
counts at baseline compared to those who were not
infected. However, at least among those children
anaemic at the baseline survey, a signiﬁcant increase
in haemoglobin counts was recorded post-treatment.
Finally the authors concluded that S. mansoni and
hookworm are indeed associated with anaemia,
which is reduced following chemotherapy. Fig. 1 il-
lustrates prevalence of anaemia by region in school-
children during four years of study with associated
95% conﬁdence intervals (CIs) for longitudinal
data of 1129 schoolchildren from Uganda. For Lake
Victoria and Albert Nile the prevalence of anaemia
has decreased signiﬁcantly at follow-up three years
later relative to baseline.
In a Niger study (Tohon et al. 2008), a detailed
analysis was performed on anaemia before and after
one treatment round, which suggests that the high
prevalence of anaemia in children from Niger is
clearly a result of many factors (e.g. infection such as
malaria and malnutrition) and not of schistosomiasis
alone. Nevertheless, treatment of schistosomiasis
and de-worming certainly contributed to the sig-
niﬁcant reduction of anaemia in schoolchildren
seen after the ﬁrst treatment. In Burkina Faso
(Koukounari et al. 2007), the relationship between
S. haematobium infection and associatedmorbidity in
children before and after the large-scale adminis-
tration of PZQ for schistosomiasis and ALB for STH
was evaluated. At baseline, higher intensities of
S. haematobium infection were observed in children
with anaemia and/or severe microhaematuria, but
there was no apparent association between the risk of
undernutrition and intensity of S. haematobium in-
fection. Signiﬁcant reductions in the prevalence and
intensity of S. haematobium infection one year after
treatment were observed. Furthermore, children
who beneﬁted the most from anthelminthic treat-
ment in terms of increased haemoglobin concen-
trations were those who had anaemia at baseline and
those with highly positive microhaematuria scores
at baseline. Separately, it was shown that the pro-
portion of school-aged children with heavy S. hae-
matobium infection, closely related to the more severe
morbidity, decreased from y25% before treatment
toy2% two years post-treatment.
Using data from Mali, ultrasound morbidity
indicators were assessed for both S. haematobium
and S. mansoni infections. In this same study the
appropriateness of the WHO coding guidelines for
ultrasound in schistosomiasis in the context of
mass chemotherapy programmes was also evaluated
(Koukounari et al. 2006b). The selection of 2247
and 2822 schoolchildren from 29 randomly chosen
schools, prior to the implementation of mass an-
thelminthic drug administration, have contributed
respectively ultrasonography data on abdominal and
urinary tract. This study found that the WHO pro-
tocol overestimates the risk of portal vein dilatation
and left liver lobe enlargement associated with
S. mansoni infection but that it proved useful for
detection of S. haematobium pathology. The authors
thus concluded that ultrasonography demonstrated
a useful tool in large-scale control interventions,
although it should be interpreted with some caution
for S. mansoni infections.
In Uganda also, longitudinal surveys on infection
status, haemoglobin concentration and clinical
morbidity in 1871 randomly selected schoolchildren
from 37 schools in eight districts were completed at
three times – before chemotherapy, one year and two
years after MDA (Kabatereine et al. 2007). This
study proved that mass de-worming with PZQ and
ALB led to a signiﬁcant decrease in the intensity of
S. mansoni and intensity of hookworm infection.
There was a signiﬁcant increase in haemoglobin
concentration after one and two years of treatment,
and a signiﬁcant decrease in signs of early clinical
Table 2. Timeline for monitoring and surveillance data by country
Completed
activities
Burkina
Faso Mali Niger Tanzania Uganda Zambia
Baseline + + + + + +
Follow-up year 1 + + + + + +
Follow-up year 2 + + + + +
Follow-up year 3 + + +
Follow-up year 4 + +
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morbidity. The impact of intervention on S. mansoni
prevalence and intensity was similar to that predicted
by mathematical models of the impact of chemo-
therapy on human schistosomiasis. Improvements
in haemoglobin concentration were greatest among
children who were anaemic or harbouring heavy
S. mansoni infection at baseline.
Drug resistance
The SCI supported implementation of mass anti-
schistosomal chemotherapy could be expected to
lead to intensive and prolonged new selection press-
ures on the parasite, including, but not exclusive to,
that for drug resistant parasites (Doenhoﬀ, Cioli and
Utzinger, 2008). Such potential evolution of drug
resistance, which has been the bane of veterinary
anthelminthics, is a particular pertinent issue for
schistosomiasis given that PZQ is the only readily
available drug (Fenwick, 2006, 2008). The reports of
development of PZQ resistance under natural con-
ditions are however inconclusive and even contro-
versial. However, some evidence has been published
from clinical investigations carried out primarily in
Egypt (Ismail et al. 1999) and Senegal ; occasional
reports of individual failures of PZQ in treatment of
travelers with schistosomiasis ; and results from some
laboratory studies reporting successful artiﬁcial-
selection of resistance lines (Fenwick and Webster,
2006).
Therefore, working closely in association with in-
country control programmes, SCI has aimed from
the outset, to monitor PZQ eﬃcacy, and genetically
and phenotypically characterize S. mansoni (and
more recently also S. haematobium) before, during
and after treatment in identiﬁable cohorts of chil-
dren. From a genetic perspective, focus has been
placed on analyses of the composition of any
apparent treatment failures, re-infecting genotypes
and the eﬀect of chemotherapy on parasite popu-
lation genetic structure. Identiﬁable cohorts of chil-
dren were selected and examined in detail, which
allowed following up known children who remain
infected after treatment. In addition, there was a
population genetics component which was set up at
the start of the SCI and which through molecular
analyses has suggested that children still infected at
follow-up are infected by diﬀerent genotypes than at
baseline; this implies reinfection not treatment fail-
ure. However, results to date indicate that even a
single round of mass-chemotherapeutic treatment
produced reductions in a range of measures of gen-
etic diversity of S. mansoni, within and across both
treated children and previously untreated children
who joined the study cohort when they became of
school-age at the ﬁrst annual follow-up. Phylogenetic
analyses and indices of population diﬀerentiation
also indicated that parasites collected in the same
schools in diﬀerent years were more dissimilar than
parasites from diﬀerent schools collectedwithin year.
Furthermore, an unexpectedly signiﬁcant genetic
bottleneck imposed by even a single round of
chemotherapeutic treatment on parasite population
structure was clearly identiﬁed. Such unique results
thereby illustrate the importance of careful genetic
monitoring and examination of even long lived
multi-cellular parasites such as these under novel or
increased selective pressures of chemotherapeutic
control programmes in order to fully understand and
predict the impact of treatment on their current and
future epidemiological dynamics.
Another dataset which SCI has collected has
concerned the costs of all the programmes, and these
results have supported the hypothesis that schisto-
somiasis and intestinal helminth control can be
achieved on a national level for less than US$ 0.50
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Fig. 1. Prevalence of anaemia* by region in schoolchildren during 4 years of study with 95% CIs
n=1129: – longitudinal data from Uganda (unpublished SCI data).
* Anaemia was deﬁned using age-stratiﬁed cut-oﬀs based on Haemacue readings (WHO, 2001). For children who
were 11 years and younger, anaemia was deﬁned as haemoglobin (Hb) being less than 115 g/l. For children aged
between 12 and 14 years, anaemia was deﬁned as haemoglobin being less than 120 g/l.
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per person for an annual treatment. Studies on cost
beneﬁts are currently underway to reinforce the
hypothesis that this is a good value for money.
EXIT STRATEGIES BY COUNTRY
The SCI strategy was to develop an intervention
programme which belonged to the countries, and
was implemented by country-appointed staﬀ housed
in the MoH or the MoE premises, using funds
transferred to the Ministries. The SCI exit strategy
in each country was originally to hand over to the
MoH a regular but reduced treatment regime tar-
geting mainly school-aged children using PZQ and
ALB. Ultimately, however SCI had to be ﬂexible in
its exit strategies due to an increase in support for the
move towards integration of NTD control using a
rapid impact package of drugs (Hotez et al. 2007a, b).
A revised exit strategy for each country involved the
schistosomiasis and STH control programmes being
absorbed into a more holistic countrywide NTD
integrated control package. This means schistoso-
miasis and STH control programmes could and
should be integrated with onchocerciasis and lym-
phatic ﬁlariasis control which requires annual doses
of ivermectin (Mectizan1) and ALB. Then, where
trachoma is also endemic, annual azithromycin
(Zithromax1) treatments could and should be added
into an integrated NTD control programme, al-
though under current recommendations all drugs
need to be spaced rather than given simultaneously.
Uganda
In Uganda, the ﬁfth and ﬁnal round of treatment
for schistosomiasis and STH with SCI support
took place in April/May 2007 in 19 districts, al-
though some treatment did take place in 2008.
By November/December 2007, the ﬁrst integrated
NTDMDA, took place where a further nine districts
were treated with PZQ andALB – mostly for the ﬁrst
time (Kabatereine et al. 2007). The MoH’s Bilharzia
and Worm Control Programme now collaborates
with the pre-existing National Onchocerciasis Con-
trol Programme; the Programme for Lymphatic
Filariasis; those from the Ministry’s Eye Depart-
ment who are responsible for trachoma control ;
and the USAID-funded NTD control programme
to implement ongoing treatment eﬀorts. Due to the
success of the treatment since 2003 the national
strategy for schistosomiasis and STH control is
being revisited to change to less frequent treatments
where prevalence and intensity of the diseases have
been greatly reduced and where annual treatment is
no longer required.
Tanzania
In Tanzania, the second and ﬁnal planned SCI
treatment took place between September and
October 2007 in the 11 selected regions. A further six
regions received their ﬁrst MDA in 2008, at which
time the evaluation of these treatments was all that
remained. SCI in 2008 and 2009 has been supporting
the MoHSW to expand coverage into the remaining
four new regions as an integrated NTD control pro-
gramme with a treatment regime targeting the other
NTDs as appropriate with a rapid impact package of
drugs. This will allow the lymphatic ﬁlariasis, the
trachoma, and the schistosomiasis and STH pro-
grammes to all expand coverage, work together, in-
tegrate their activities and improve the health of all
the targeted populations. In the previously treated
areas, integration will gradually develop based on the
anticipated success of the newly developed NTD
control programme.
Zambia
In Zambia, the second round of treatment for
schistosomiasis and STH occurred in July 2007 in
19 districts in Eastern and Southern provinces.
Zambia has been less successful in reaching its
original programme target of expanding coverage to
treating 2 million school-aged individuals and had
only achieved, according to incompletely reported
coverage, around 25% of this target by July 2007,
which might be partially explained by diﬃculties
in obtaining reliable treatment data from the ﬁeld.
The reasons and lessons learned are that there was no
full-time national co-ordinator in the MoH or MoE
dedicated to the programme, there was also no
full-time national programme team dedicated to the
programme, no full-time support team and therefore
management was not suﬃciently dynamic to achieve
the targets. The training of CDDs and teachers
in rural areas turned out to be signiﬁcantly more
expensive than in other SCI-supported countries
which meant that the cost per person treated was, in
Zambia, signiﬁcantly higher than the under US$
0.50 achievable in neighbouring countries. The SCI
exited by handing over the programme to the MoH
in the hope that they would continue to support the
SHN programme, however at the time whether the
treatment strategy was to continue was dependent on
internal and external funding and the appointment
of a full-time national co-ordinator in the Zambian
government (in the opinion of the authors).
Since mid-2008, a newly appointed full-time
NTD coordinator at the MoH and a ‘School Health
and Nutrition Coordinator’ at the MoE have over-
seen the expansion of the programme into four new
provinces. In these provinces, Luapula, Northern,
Northwestern and Western, small-scale treatment
for schistosomiasis and STH has been implemented.
The current strategy by the MoH is to seek further
funds for the treatment of these diseases along with
the other endemic NTDs in the country with an
integrated control programme proposal.
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Burkina Faso
Burkina Faso had its ﬁrst nationwide coverage
for schistosomiasis and STH treatment in two
years: 2004 and 2005 using PZQ and ALB. During
2006–2008 the second SCI-funded treatment of over
2.5 million school-aged children in nine regions was
completed. The exit strategy involved not only the
hand-over of the programme to a newly established
NTD department at the MoH, but also the estab-
lishment for the ﬁrst time of a trachoma mapping
and control programme, funded by the USAID
NTD programme, managed by SCI and in-country
NGO partner Reseau International Schistosomoses
Environnement Amenagements et Lutte (RISEAL-
http://www.riseal.org/). For lymphatic ﬁlariasis and
onchocerciasis, Burkina Faso covered the whole
country every year since 2003.
Mali
In Mali, the ﬁnal SCI funded treatment solely for
schistosomiasis and STH was in 2007 both before
and during the hand over to the integrated NTD
control programme supported by USAID. SCI
handed the programme over to ‘new management’
appointed by USAID so that the schistosomiasis and
STH control could be incorporated into the new
NTD department within the MoH.
Niger
In Niger, the ﬁnal targeted treatment for schistoso-
miasis and STH was in 2007. The treatment cam-
paign took place at the same time as the integrated
NTD campaign, but targeted diﬀerent geographical
regions (Agadez, Diﬀa and Zinder). The ﬁnal treat-
ment ensured that all SCI planned target groups had
been treated twice with PZQ and ALB, and the exit
strategy for the SCI-supported schistosomiasis and
STH programme was to integrate with the existing
trachoma programme and the newly-established
lymphatic ﬁlariasis control programme, and this has
now been incorporated into the NTD department
during 2008 and expanded rapidly towards a national
coverage.
CONCLUSION
The SCI was established to assist selected African
countries to develop a sustainable schistosomiasis
control programme within their existing health sys-
tems. In the short term, SCI has helped to imple-
ment vertical programmes in all six aforementioned
countries, leading to integrated programmes eventu-
ally absorbed into the MoH structures. During
its years of operation so far, the SCI and partners
have demonstrated that preventive chemotherapy
with PZQ and ALB makes a signiﬁcant diﬀerence to
health of school-aged children and other risk popu-
lations in the short term and we believe possible
health eﬀects will be sustained in the longer term.
Studies suggest that treatment does create a demand
for more treatment by raising the awareness of these
diseases and the knowledge of control in the target
populations (Zhang et al. 2007; Toure´ et al. 2008).
With a ﬂexible attitude to progress, SCI believes that
the best ways to tackle schistosomiasis and STHhave
been assessed, and shown to be successful, with each
country selecting their preferred target population
based on epidemiological evidence.
With the success and progress of the SCI pro-
gramme in these countries, and the parallel successes
of programmes against onchocerciasis, trachoma and
lymphatic ﬁlariasis, it was realized that a close col-
laboration leading to integration of the in-country
existing vertical programmes might lead to expanded
coverage, cost savings and less burdensome mana-
gement (Fenwick, 2006; Lammie, Fenwick and
Utzinger, 2006). Therefore, current and future
rounds of treatment in all six countries are being
delivered in an integrated manner to include
schistosomiasis, STH, lymphatic ﬁlariasis, oncho-
cerciasis and trachoma.
For the future, SCI has used its ﬁrst award from
the BMGF, to achieve severalmission objectives, but
also to secure co-funding for new treatment pro-
grammes from other major donors. In the future,
SCI plans to assist countries to fund the implemen-
tation of NTD control with grants from the USAID
and others, while continuing to provide in-depth
monitoring and evaluation.
In conclusion, the strategies for the control of
schistosomiasis have been and remain focused on
preventive chemotherapy. As of 2009 however,
schistosomiasis and STH are no longer considered
in isolation. While challenges remain, the case for
the control of schistosomiasis and STH has been
strengthened by research within SCI and the prin-
ciple that a national programme using preventive
chemotherapy can be successfully implemented in
sub-SaharanAfrica whenever the resources are avail-
able. SCI and partners are now continually striving
to raise further funds to expand the coverage of in-
tegrated control of NTDs in sub-SaharanAfrica. For
sustainable control it will be necessary for each
country to have access to the drugs and resources for
delivery on a long term basis, during which time the
infrastructure for health systems, improved water
and sanitation will need to be developed if schisto-
somiasis is to be removed as a public health problem.
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